Division of Emerging Research Advanced Research & Development Programs for Medical Innovation(AMED-CREST)

Promotion and support of this Research and Development (R&D) Area was transferred from the Japan Science and Technology Agency (JST) as of April 1, 2015. The original English texts were based on those provided by the courtesy of JST.

Development of Fundamental Technologies for Diagnosis and Therapy Based upon Epigenome Analysis

[Research and Development Objective] Creation of the basic technologies for disease analysis and elucidation of stem cell differentiation mechanisms by using epigenomic comparison toward the realization of treatments and regenerative medicine used to prevent, diagnose, and treat diseases

Outline of the Research & Development (R&D) Area

For healthy life and development of novel strategies for disease prevention, diagnosis, and therapy, this R&D area focuses on discovery of new principles and establishment of fundamental medical technologies based on epigenome analyses accompanied by biological analyses.

Specifically, this R&D area invites proposals that identify epigenome alterations useful for identification of etiologies or those critically involved in development and progression of cancers or other chronic disorders, such as arteriosclerosis, diabetes, neurological diseases, and autoimmune diseases. The findings should lead to identification of novel mechanisms for induction of epigenome alteration or maintenance of epigenomes or to innovative strategies for disease prevention, diagnosis, and therapy. This area also invites proposals that, by comparing epigenome profiles during stem cell differentiation, reveal mechanisms of cellular differentiation and establish technologies for robust directed differentiation of various cells to specific lineages. Furthermore, this area invites proposals that develop key technologies for more efficient analysis of methylomes and histone modifications, and for control of epigenomes.

In this R&D area, AMED cooperates with the International Human Epigenome Consortium (IHEC) through some proposals.

Year the Area adopted


Management and Evaluation Framework

Program Supervisor (PS)

Masayuki Yamamoto
Dean / Professor, Tohoku University

Program Officer (PO)

Toshikazu Ushijima
Chief of Division, National Cancer Center Research Institute

R&D Area Advisors

Toshihisa Takagi
Professor, The University of Tokyo
Masayo Takahashi
Project Leader, RIKEN
Shoji Tajima
Professor, Osaka University
Tsutomu Chiba
Professor, Kyoto University
Kazumi Nishijima
Manager, Mochida Pharmaceutical Co., Ltd.
Akiyoshi Fukamizu
Professor, University of Tsukuba
Hozumi Motohashi
Professor, Tohoku University
Ken-ichirou Morohashi
Professor, Kyushu University
Minoru Yoshida
Chief Scientist, RIKEN


Last updated 2018.2.21